Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Conversational AI for remote monitoring in heart failure: a prospective controlled pilot study
0
Zitationen
16
Autoren
2026
Jahr
Abstract
Abstract Aims Heart failure (HF) requires scalable strategies to detect decompensation early and reduce hospitalizations. Existing telemonitoring tools are often invasive, complex, or poorly integrated into routine care. To evaluate the feasibility and clinical impact of a conversational artificial intelligence system (CAIS) for automated telephone follow-up in patients with HF. Methods and results We conducted a prospective, non-randomized, controlled feasibility study at a tertiary hospital. Eighty-six outpatients received weekly AI-assisted follow-up via natural language processing calls, collecting symptoms and vital signs. Alerts were reviewed by HF nurses, who determined responses per standard practice. Forty patients received usual care. The primary objective was feasibility and acceptability; exploratory endpoints included all-cause death, cardiovascular death, HF hospitalization, and diuretic intensification at 12 months, analysed with Cox and competing-risks regression. Of 4272 scheduled calls, 3919 were completed (91.7%). CAIS generated 1962 alerts, prompting 648 actions—mainly nurse calls (86.6%) and medication changes (7.9%). Nurse workload was 2.4 min/patient/week. At 12 months, the CAIS group improved KCCQ-12 score by +7.13 points (95% CI 1.19–13.07; P = 0.019), while EQ-5D-5L and PHQ-4 showed no significant change. Satisfaction was high (mean 8.72 ± 1.81). The intervention group had fewer all-cause death or HF hospitalization events (HR 0.39; 95% CI 0.16–0.96; P = 0.041) and lower cardiovascular mortality (1.2% vs. 10.0%; P = 0.035), with a non-significant trend towards fewer HF hospitalizations (sHR 0.43; 95% CI 0.16–1.13; P = 0.087). Conclusion CAIS follow-up was feasible, well-received, and low-resource, with exploratory signals of improved outcomes. This pragmatic, scalable approach may enhance HF care and warrants validation in randomized trials.
Ähnliche Arbeiten
Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.
2021 · 19.535 Zit.
2013 ACCF/AHA Guideline for the Management of Heart Failure
2013 · 12.581 Zit.
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
2021 · 12.105 Zit.
Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?
2016 · 11.730 Zit.
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
2002 · 11.655 Zit.
Autoren
- Aleix Olivella
- Ana B Méndez Fernández
- Emmanuel Giménez García
- Alonso Ortega Torregimeno
- Eduard Ródenas-Alesina
- Raúl Aguilar López
- Tania Maza Pelaez
- Toni Soriano-Colomé
- Augusto Sao Avilés
- Aitor Bilbao Uribarri
- Teresa Soriano Sánchez
- Cristina Bocanegra
- Eva Domingo Baldrich
- Maria José Martinez-Zapata
- María Rubio-Valera
- Ignacio Ferreira‐González
Institutionen
- Hebron University(PS)
- Universitat Autònoma de Barcelona(ES)
- Vall d'Hebron Institut de Recerca(ES)
- Vall d'Hebron Hospital Universitari(ES)
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias(ES)
- Centro de Investigación Biomédica en Red(ES)
- Iberoamerican Cochrane Centre(ES)
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública(ES)
- Parc Sanitari Sant Joan de Déu(ES)